Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 28,851 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Clear all
Completed Not applicable Interventional Accepts healthy volunteers

ConnectEd: A Randomized Controlled Trial Connecting Through Educational Training

NCT02786472
View directory record Official record
Conditions
Sexual Violence
Interventions
Online Bystander Training, Online Substance Abuse Training, In-Person Bystander Training, In-Person Combination Training
Behavioral
Lead sponsor
Heather Bush
Other
Eligibility
17 Years to 24 Years
Enrollment
3,178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 4 Interventional Results available

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

NCT01221272
View directory record Official record
Conditions
Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions
Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise
Drug · Procedure · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Microdialysis and Pharmacokinetic Study of TR-701

NCT00666601
View directory record Official record
Conditions
Healthy
Interventions
TR-700 (active moiety), TR-701 (pro-drug)
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

NCT02872701
View directory record Official record
Conditions
Lung Neoplasms, Lung Cancer
Interventions
OTL38 for Injection, Near infrared camera imaging system, Endoscopic or Thoracic Surgery
Drug · Device · Procedure
Lead sponsor
On Target Laboratories, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 30, 2026, 11:38 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System

NCT04401865
View directory record Official record
Conditions
Corneal Ectasia, Keratoconus, Pellucid Marginal Corneal Degeneration
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Colorado Eye Consultants/Cornea Consultants of Colorado
Industry
Eligibility
8 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Littleton, Colorado • Highland Park, Illinois • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 30, 2026, 11:38 AM EDT
Completed No phase listed Observational

Manipulating Cognitive Intensity During Aerobic Exercise

NCT06479265
View directory record Official record
Conditions
Cognitive Decline
Interventions
Phyical/Cognitve Exercise
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 4 Interventional

Carbamazepine Extended-Release for the Treatment of Bipolar Depression

NCT00203567
View directory record Official record
Conditions
Bipolar Depression
Interventions
carbamazepine ER
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 24, 2008 · Synced Oct 30, 2026, 11:38 AM EDT
Terminated Phase 2 Interventional

Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)

NCT04990167
View directory record Official record
Conditions
Asthma in Children
Interventions
Tiotropium Bromide
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 11 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

NCT00842400
View directory record Official record
Conditions
Obesity
Interventions
Metformin, VI-0521, Sitagliptan, Probenecid
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 21, 2010 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Not applicable Interventional Results available

Lifestyle Program for Obstructive Sleep Apnea With Severe Obesity

NCT05343000
View directory record Official record
Conditions
Obstructive Sleep Apnea, Obesity
Interventions
Home-based pulmonary rehabilitation (PR) system
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 2 Interventional

RCT Comparing ESPB Solutions in Breast Surgery

NCT04603911
View directory record Official record
Conditions
Breast Cancer
Interventions
Liposomal bupivacaine, Bupivacaine, epinephrine, dexamethasone, and clonidine
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 30, 2026, 11:38 AM EDT
Recruiting Not applicable Interventional

SISTER: Sibling Oocyte Insemination With Frozen Sperm From Third Party Donors: Evaluation of Reproductive Techniques

NCT07175571
View directory record Official record
Conditions
Infertility, Female, Reproductive Techniques, Assisted, Fertilization in Vitro
Interventions
Intracytoplasmic Sperm Injection (ICSI), Conventional Insemination (IVF)
Procedure
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Other
Eligibility
Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 30, 2026, 11:38 AM EDT
Completed No phase listed Observational

Urinary Kidney Injury Molecule-1 (KIM-1) Excretion As Biomarker for Injury in Kidney Transplant Recipients

NCT00805571
View directory record Official record
Conditions
Kidney Transplant Dysfunction
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2010 · Synced Oct 30, 2026, 11:38 AM EDT
Recruiting Phase 2 Interventional

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

NCT03150511
View directory record Official record
Conditions
Peripheral Nerve Injuries
Interventions
Tesamorelin 2 Milligrams (MG)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Naltrexone for Individuals of East Asian Descent

NCT02026011
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 30, 2026, 11:38 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Naproxen Pharmacogenetic Study (Project 1, Aim 2)

NCT04449471
View directory record Official record
Conditions
Pharmacogenetics
Interventions
Naproxen tablet
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 30, 2026, 11:38 AM EDT
Terminated Phase 2 Interventional Results available

Antidepressant Effects of TS-161 in Treatment-Resistant Depression

NCT04821271
View directory record Official record
Conditions
Major Depressive Disorder, Treatment-Resistant Depression, Depression
Interventions
Placebo, TS-161
Other · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

NCT03882762
View directory record Official record
Conditions
Pharmacokinetic
Interventions
Cebranopadol 200 μg tablet
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 30, 2026, 11:38 AM EDT
Completed Phase 1 Interventional

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

NCT03262103
View directory record Official record
Conditions
Prostate Cancer
Interventions
Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC, Radical Prostatectomy
Biological · Procedure
Lead sponsor
Ashutosh Kumar Tewari
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 30, 2026, 11:38 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population

NCT06744673
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Pregnancy
Interventions
No Intervention
Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
16 Years to 49 Years · Female only
Enrollment
861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 30, 2026, 11:38 AM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

NCT03911466
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 30, 2026, 11:38 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pain, Opioids and Pro-Inflammatory Immune Responses

NCT01210066
View directory record Official record
Conditions
Pro-inflammatory Activity, Immunologic Activity Alteration
Interventions
Fentanyl, Cold pressor test, Fentanyl plus cold pressor test
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 30, 2026, 11:38 AM EDT
Active, not recruiting Phase 2 Interventional

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions
decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax, INQOVI (oral decitabine)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Portland, Oregon • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 30, 2026, 11:38 AM EDT